Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.
Lee CV, Koenig P, Fuh G. Lee CV, et al. MAbs. 2014 May-Jun;6(3):622-7. doi: 10.4161/mabs.28483. Epub 2014 Mar 11. MAbs. 2014. PMID: 24618680 Free PMC article.
Bivalent antibody phage display mimics natural immunoglobulin.
Lee CV, Sidhu SS, Fuh G. Lee CV, et al. J Immunol Methods. 2004 Jan;284(1-2):119-32. doi: 10.1016/j.jim.2003.11.001. J Immunol Methods. 2004. PMID: 14736422
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.
Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. Lee CV, et al. J Mol Biol. 2004 Jul 23;340(5):1073-93. doi: 10.1016/j.jmb.2004.05.051. J Mol Biol. 2004. PMID: 15236968
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G. Liang WC, et al. Among authors: lee cv. J Biol Chem. 2006 Jan 13;281(2):951-61. doi: 10.1074/jbc.M508199200. Epub 2005 Nov 7. J Biol Chem. 2006. PMID: 16278208
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.
Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C. Fuh G, et al. Among authors: lee cv. J Biol Chem. 2006 Mar 10;281(10):6625-31. doi: 10.1074/jbc.M507783200. Epub 2005 Dec 22. J Biol Chem. 2006. PMID: 16373345
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.
Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, DeForge LE, Martin F, Starovasnik MA, Fuh G. Lee CV, et al. Blood. 2006 Nov 1;108(9):3103-11. doi: 10.1182/blood-2006-03-011031. Epub 2006 Jul 13. Blood. 2006. PMID: 16840730
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.
Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N. Gerber HP, et al. Among authors: lee cv. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83. doi: 10.1073/pnas.0611492104. Epub 2007 Feb 20. Proc Natl Acad Sci U S A. 2007. PMID: 17360669 Free PMC article.
Improving antibody binding affinity and specificity for therapeutic development.
Bostrom J, Lee CV, Haber L, Fuh G. Bostrom J, et al. Among authors: lee cv. Methods Mol Biol. 2009;525:353-76, xiii. doi: 10.1007/978-1-59745-554-1_19. Methods Mol Biol. 2009. PMID: 19252851
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G. Bostrom J, et al. Among authors: lee cv. Science. 2009 Mar 20;323(5921):1610-4. doi: 10.1126/science.1165480. Science. 2009. PMID: 19299620
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. Schaefer G, et al. Among authors: lee cv. Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003. Cancer Cell. 2011. PMID: 22014573
34 results
Jump to page